# Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

> **NCT02858869** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Mucosal Melanoma
- Ocular Melanoma
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Skin Melanoma
- Melanoma of Unknown Primary

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT02858869
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-04
- **Primary completion:** 2020-11-19
- **Final completion:** 2023-10-28
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858869, "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02858869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*